Connect with us

Hi, what are you looking for?

press release

Santhera and ReveraGen Announce Presentations on Long-Term

#Santhera #ReveraGen #Announce #Presentations #LongTerm

Pratteln, Switzerland, and Rockville, MD, USA, October 1
0, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of data relating to long-term efficacy, tolerability and the impact of vamorolone on bone health in patients with Duchenne muscular dystrophy (DMD) over 2.5 years of treatment [1].

The data will be shared at the 2022 World Muscle Society (WMS) Congress being held October 11-15, 2022, in Halifax, Nova Scotia, Canada, as follows:

Flash poster presentations

The spine fracture burden in boys with DMD treated with the novel dissociative steroid vamorolone versus deflazacort and prednisone – Leanne Ward, MD, October 12, 14:40-14:45 ADT, #FP.03

Results of a double-blind cross-over trial of vamorolone in Duchenne muscular dystrophy (DMD) – Eric Hoffman, PhD, October 14, 14:40-14:45 ADT, #FP.27


Vamorolone’s impact on height and body mass index in patients with Duchenne muscular dystrophy (DMD) – Ward L et al, October 12, 16:00-17:30 ADT, #P.71

Result of daily regimens of prednisone, deflazacort, and vamorolone on motor function in patients with Duchenne muscular dystrophy – McDonald C et al, October 14, 14:30-16:00 ADT, #P.133

Presentations and posters will be available under this link from October 11, 2022, 16:00 ADT.

“The data being presented by our academic collaborators will foster further understanding of the potential of a dissociative steroid, such as vamorolone, in maintaining muscle strength whilst addressing important safety concerns in the treatment of DMD,” said Shabir Hasham, MD, Chief Medical Officer of Santhera.

Santhera is hosting an on-site scientific exhibit (booth #4, located in the Ballroom Salon) where medical representatives of the Company will be present throughout the conference.

About Vamorolone
Vamorolone is an investigational drug candidate with a mode of action based on binding to the same receptor as corticosteroids but modifying its downstream…

Read on GNW: Santhera and ReveraGen Announce Presentations on Long-Term

You May Also Like

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.


State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

Health News

The cosmetic and facial plastic surgery practice is hosting a grand opening celebration and ribbon cutting for its new Chattanooga state-of-the-art location.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...